<- Go Home
HilleVax, Inc.
HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. It has a license agreement with Takeda for the commercialization of any pharmaceutical products with HIL-214 compounds. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.
Market Cap
$94.7M
Volume
429.9K
Cash and Equivalents
$47.5M
EBITDA
-$78.4M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$16.30
52 Week Low
$1.34
Dividend
N/A
Price / Book Value
0.63
Price / Earnings
-0.89
Price / Tangible Book Value
0.63
Enterprise Value
-$40.8M
Enterprise Value / EBITDA
0.54
Operating Income
-$80.1M
Return on Equity
54.64%
Return on Assets
-20.31
Cash and Short Term Investments
$159.5M
Debt
$24.0M
Equity
$150.9M
Revenue
N/A
Unlevered FCF
-$48.1M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium